ESEmily J. Su

Emily J. Su

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emily J. Su has a total of 110 co-authors. Here are the top co-authors by number of shared publications:

  • Amanda R. Flockton

    Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, CO 80045, USA

    2 shared publications
  • Diane Gumina

    University of Colorado School of Medicine 1 Division of Reproductive Sciences, Department of Obstetrics and Gynecology Aurora, CO 80045 , USA

    2 shared publications
  • Diane L. Gumina

    Department of Obstetrics and Gynecology, University of Colorado School of Medicine, CO, U.S.A.

    2 shared publications
  • Diane L. Gumina

    Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, CO 80045, USA

    2 shared publications
  • Hong Xin

    Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, 12361 E. 17th Avenue, B198-5, Aurora, CO 80045, U.S.A.

    2 shared publications
  • Kathryn McPeak

    University of Colorado School of Medicine 1 Division of Reproductive Sciences, Department of Obstetrics and Gynecology Aurora, CO 80045 , USA

    2 shared publications

Latest Publications

  • Open Access

    Unraveling the Matrix: Proteomic Profiling Reveals Stromal ECM Dysregulation in Severe Early-Onset Fetal Growth Restriction

    by Stefano Ginocchio, Maxwell C. McCabe, Amanda R. Flockton, Diane L. Gumina, Kirk C. Hansen, Shuhan Ji, Emily J. Su

    An underdeveloped placental vasculature is a cardinal feature in severe, early-onset fetal growth restriction with absent/reversed umbilical artery Doppler end-diastolic velocities (FGRa/r). Tissue microenvironment is a key mediator of angiogenesis; yet, the role of placental villous stromal extracellular matrix (ECM) in FGRa/r remains unknown. We applied an ECM-optimized, proteomic workflow to villous tissue and placental fibroblast cell-derived matrices (CDM) from FGRa/r, gestational age-matched controls, and uncomplicated term pregnancies. No significant differences were detected in villous tissue, although there was a trend toward increased type I collagen and fibronectin in FGRa/r placentas. FGRa/r CDM, however, appeared distinct from both control groups, with elevated matrisome abundance, greater insolubility of matrisome-associated proteins, and 44 differentially expressed matrisome proteins. Fibronectin emerged as a central network hub among differential matrisome proteins, interacting with thrombospondin-1, vitronectin, and transglutaminase-2, all of which were enriched in FGRa/r CDM, suggesting excessive deposition and crosslinking. In contrast, regulators of ECM remodeling and TGFβ activity, including fibrillin-1, decorin, and syndecan-4, were depleted. These features suggest a pro-fibrotic, dysregulated stroma with diminished remodeling capacity. Our findings establish the first, comprehensive proteomic map of human placental stromal matrisome and provide a molecular framework for understanding how aberrant ECM organization contributes to placental dysfunction.


  • Open Access

    Advice to people with Parkinson's in my clinic: How to manage running-induced dystonia

    by Michele L Callisaya, Jane Alty, Dave de Groot, Guillaume Lamotte, Nijee Luthra, Kathleen E McKee, Emily J Su, Daniel M Corcos

    Exercise is an essential part of the treatment of Parkinson's disease. However, certain symptoms can make exercise difficult. In this viewpoint, we describe an under recognized symptom called running-induced dystonia (RID), which can prevent people with Parkinson's from exercising in their preferred way. We summarize the existing literature and use three case studies to outline potential mechanisms, aggravating and relieving factors and both pharmacological and non-pharmacological therapies to get rid of RID.

  • Placental differences between severe fetal growth restriction and hypertensive disorders of pregnancy requiring early preterm delivery: morphometric analysis of the villous tree supported by artificial intelligence

    by Anna Jacobs, Saif I. Al-Juboori, Evgenia Dobrinskikh, Matthew A. Bolt, Mary D. Sammel, Virginia Lijewski, Miriam D. Post, James M. Small, Emily J. Su


  • Open Access

    Angiogenic Function of Human Placental Endothelial Cells in Severe Fetal Growth Restriction Is Not Rescued by Individual Extracellular Matrix Proteins

    by Lauren Sayres, Amanda R. Flockton, Shuhan Ji, Carla Rey Diaz, Diane L. Gumina, Emily J. Su

    Severe fetal growth restriction (FGR) is characterized by increased placental vascular resistance resulting from aberrant angiogenesis. Interactions between endothelial cells (ECs) and the extracellular matrix (ECM) are critical to the complex process of angiogenesis. We have previously found that placental stromal abnormalities contribute to impaired angiogenesis in severe FGR. The objective of this research is to better characterize the effect of individual ECM proteins on placental angiogenic properties in the setting of severe FGR. ECs were isolated from human placentae, either control or affected by severe FGR, and subjected to a series of experiments to interrogate the role of ECM proteins on adhesion, proliferation, migration, and apoptosis. We found impaired proliferation and migration of growth-restricted ECs. Although individual substrates did not substantially impact migratory capacity, collagens I, III, and IV partially mitigated proliferative defects seen in FGR ECs. Differences in adhesion and apoptosis between control and FGR ECs were not evident. Our findings demonstrate that placental angiogenic defects that characterize severe FGR cannot be explained by a singular ECM protein, but rather, the placental stroma as a whole. Further investigation of the effects of stromal composition, architecture, stiffness, growth factor sequestration, and capacity for remodeling is essential to better understand the role of ECM in impaired angiogenesis in severe FGR.


  • Open Access

    Scaling the EVERREST of severe, early-onset fetal growth restriction

    by Emily J. Su

    Severe, early-onset fetal growth restriction is a leading cause of medically indicated preterm birth and substantially increases the risk for perinatal death or disability. No treatments exist to improve fetal growth or safely prolong pregnancy. Furthermore, wide-ranging phenotypes limit the accurate prediction of pregnancy outcome. In this issue of the JCI, Spencer and colleagues combine a discovery-science approach with ultrasound parameters to identify the most discriminative models for predicting either the primary outcome of fetal or neonatal death, or a secondary outcome of death or delivery at 28 weeks of gestation or earlier. Their findings can better individualize patient counseling but, just as compellingly, provide the capacity to identify those pregnancies that are at such considerable risk as to justify enrollment in paradigm-shifting interventional trials that are in the pipeline.


  • Mechanistic insights into the development of severe fetal growth restriction

    by Diane L. Gumina, Emily J. Su

    Fetal growth restriction (FGR), which most commonly results from suboptimal placental function, substantially increases risks for adverse perinatal and long-term outcomes. The only “treatment” that exists is delivery, which averts stillbirth but does not improve outcomes in survivors. Furthermore, the potential long-term consequences of FGR to the fetus, including cardiometabolic disorders, predispose these individuals to developing FGR in their future pregnancies. This creates a multi-generational cascade of adverse effects stemming from a single dysfunctional placenta, and understanding the mechanisms underlying placental-mediated FGR is critically important if we are to improve outcomes and overall health. The mechanisms behind FGR remain unknown. However, placental insufficiency derived from maldevelopment of the placental vascular systems is the most common etiology. To highlight important mechanistic interactions within the placenta, we focus on placental vascular development in the setting of FGR. We delve into fetoplacental angiogenesis, a robust and ongoing process in normal pregnancies that is impaired in severe FGR. We review cellular models of FGR, with special attention to fetoplacental angiogenesis, and we highlight novel integrin-extracellular matrix interactions that regulate placental angiogenesis in severe FGR. In total, this review focuses on key developmental processes, with specific focus on the human placenta, an underexplored area of research.


  • Open Access

    Clinical validation of novel second-trimester preterm preeclampsia risk predictors combining clinical variables and serum protein biomarkers

    by Louise C. Laurent, George R. Saade, Glenn R. Markenson, Kent D. Heyborne, Corina N. Schoen, Jason K. Baxter, Sherri A. Longo, Leonardo M. Pereira, Emily J. Su, Matthew K. Hoffman, et al.

    Background Clinical risk factors for preeclampsia (PE), including previous PE, chronic hypertension, and pregestational diabetes, are poorly predictive of PE. Preterm PE, defined as diagnosis of PE with delivery prior to 37 weeks’ gestational age (GA), is more likely to be associated with serious morbidities and difficult clinical decision making. Therefore, there remains an urgent clinical need to develop a safe, feasible, and accurate predictor of preterm PE that integrates molecular biomarkers and relevant clinical factors into a single risk assessment score that can be used to guide clinical management. Objective(s) To discover, verify, and validate a mid-trimester proteomic biomarker risk predictor for preterm PE, comprised of a composite clinical variable and a small number of maternal serum analytes. Study Design This was a secondary analysis of data from two large clinical trials (PAPR, NCT02787213; TREETOP, NCT01371019). PAPR subjects’ eligibility was limited to those who had consented to research into preterm birth and pregnancy complications and who had blood drawn between 180/7 – 226/7 weeks’ gestation. TREETOP subjects were limited to those who had blood drawn between 180/7 – 206/7weeks’ gestation. PAPR subjects were assigned to a discovery cohort, and TREETOP subjects were randomly assigned to a first-phase cohort for verification (comprised of one-third of eligible subjects) and to a separate second-phase cohort for validation (comprised of the remaining two-thirds of eligible subjects). Peptides were analyzed by liquid chromatography-multiple reaction monitoring mass spectrometry measuring 77 pregnancy-related proteins and quality control proteins. Models were limited to a maximum of one additional protein ratio and a composite clinical variable, referred to as Clin3, which was deemed positive if any of three factors was true for the subject: prior PE; pre-existing hypertension; and/or pregestational diabetes. Overall classifier performance was assessed via area under the receiver operating characteristic curve (AUC). Results Verification yielded nine multi-component classifier models for prediction of preterm PE, all of which were subsequently validated. Classifiers exhibited greater predictive performance than clinical factors alone. Example performance metrics across a range of classifier score thresholds and GA at birth cutoffs of 37, 34 and 32 weeks for the Clin3 + inhibin subunit beta c (INHBC)/SHBG classifier, which showed the highest AUC, demonstrating a sensitivity of 89% at a specificity of 75% for prediction of early-onset preeclampsia (Conclusion(s) Here, we report on discovery, verification, and validation of models for prediction of preterm PE. The log ratio of INHBC/SHBG along with any one of three clinical risk factors demonstrated high sensitivity and specificity. This combination of protein biomarkers and clinical factors has the potential to be used in the mid-trimester of pregnancy to guide clinical management to avoid both unnecessary medical procedures and the most serious complications of early-onset PE.

  • Open Access

    Dysregulation of integrin αvβ3 and α5β1 impedes migration of placental endothelial cells in fetal growth restriction

    by Diane L. Gumina, Shuhan Ji, Amanda Flockton, Kathryn McPeak, Dominik Stich, Radu Moldovan, Emily J. Su

    Placentas from pregnancies complicated by severe early-onset fetal growth restriction (FGR) exhibit diminished vascular development mediated by impaired angiogenesis, but underlying mechanisms remain unknown. In this study, we show that FGR endothelial cells demonstrate inherently reduced migratory capacity despite the presence of fibronectin, a matrix protein abundant in placental stroma that displays abnormal organization in FGR placentas. Thus, we hypothesized that aberrant endothelial-fibronectin interactions in FGR are a key mechanism underlying impaired FGR endothelial migration. Using human fetoplacental endothelial cells isolated from uncomplicated term control and FGR pregnancies, we assessed integrin α5β1 and αvβ3 regulation during cell migration. We show that endothelial integrin α5β1 and αvβ3 interactions with fibronectin are required for migration and that FGR endothelial cells responded differentially to integrin inhibition, indicating integrin dysregulation in FGR. Whole-cell expression was not different between groups. However, there were significantly more integrins in focal adhesions and reduced intracellular trafficking in FGR. These newly identified changes in FGR endothelial cellular processes represent previously unidentified mechanisms contributing to persistent angiogenic deficiencies in FGR.


  • Open Access

    Performance of a Multianalyte ‘Rule-Out’ Assay in Pregnant Individuals With Suspected Preeclampsia

    by Maged M. Costantine, Baha Sibai, Allan T. Bombard, Mark Sarno, Holly West, David M. Haas, Alan T. Tita, Erin A.S. Clark, Kim Boggess, Chad Grotegut, et al.

    Background: The ability to diagnose preeclampsia clinically is suboptimal. Our objective was to validate a novel multianalyte assay and characterize its performance, when intended for use as an aid to rule-out preeclampsia. Methods: Prospective, multicenter cohort study of pregnant individuals presenting between 28 0/7 and 36 6/7 weeks’ with preeclampsia-associated signs and symptoms. Individuals not diagnosed with preeclampsia after baseline evaluation were enrolled in the study cohort, with those who later developed preeclampsia, classified as cases and compared with a negative control group who did not develop preeclampsia. Individuals with assay values at time of enrollment ≥0.0325, determined using a previously developed algorithm, considered at risk. The primary analysis was the time to develop preeclampsia assessed using a multivariate Cox regression model. Results: One thousand thirty-six pregnant individuals were enrolled in the study cohort with an incidence of preeclampsia of 30.3% (27.6%–33.2%). The time to develop preeclampsia was shorter for those with an at-risk compared with negative assay result (log-rank P P <0.0001]). The performance metrics for the assay to rule-out preeclampsia within 7 days of enrollment showed a sensitivity 76.4% (67.5%–83.5%), negative predictive value 95.0% (92.8%–96.6%), and negative likelihood ratio 0.46 (0.32–0.65). Assay performance improved if delivery occurred <37 weeks and for individuals enrolled between 28 and 35 weeks. Conclusions: We confirmed that a novel multianalyte assay was associated with the time to develop preeclampsia and has a moderate sensitivity and negative likelihood ratio but high negative predictive value when assessed as an aid to rule out preeclampsia within 7 days of enrollment. Registration: The study was registered on Clinicaltrials.gov (Identifier NCT02780414).


  • Vascular Disorders of Pregnancy Increase Susceptibility to Neonatal Pulmonary Hypertension in High-Altitude Populations

    by Alexandra Heath-Freudenthal, Lilian Toledo-Jaldin, Inge von Alvensleben, Litzi Lazo-Vega, Rodrigo Mizutani, Margaret Stalker, Hussna Yasini, Fanny Mendizabal, Jesus Dorado Madera, William Mundo, et al.

    Background: Preeclampsia and fetal growth restriction increase cardiopulmonary disease risk for affected offspring and occur more frequently at high-altitude (≥2500 m). Retrospective studies indicate that birth to a preeclampsia woman at high altitude increases the risk of pulmonary hypertension (PH) in later life. This prospective study asked whether preeclampsia with or without fetal growth restriction exaggerated fetal hypoxia and impaired angiogenesis in the fetal lung, leading to neonatal cardiopulmonary circulation abnormalities and neonatal or infantile PH. Methods and Results: We studied 79 maternal-infant pairs (39 preeclampsia, 40 controls) in Bolivia (3600–4100 m). Cord blood erythropoietin, hemoglobin, and umbilical artery and venous blood gases were measured as indices of fetal hypoxia. Maternal and cord plasma levels of angiogenic (VEGF [vascular endothelial growth factor]) and antiangiogenic (sFlt1 [soluble fms-like tyrosine kinase]) factors were determined. Postnatal echocardiography (1 week and 6–9 months) assessed pulmonary hemodynamics and PH. Preeclampsia augmented fetal hypoxia and increased the risk of PH in the neonate but not later in infancy. Pulmonary abnormalities were confined to preeclampsia cases with fetal growth restriction. Maternal and fetal plasma sFlt1 levels were higher in preeclampsia than controls and positively associated with PH. Conclusions: The effect of preeclampsia with fetal growth restriction to increase fetal hypoxia and sFlt1 levels may impede normal development of the pulmonary circulation at high altitude, leading to adverse neonatal pulmonary vascular outcomes. Our observations highlight important temporal windows for the prevention of pulmonary vascular disease among babies born to highland residents or those with exaggerated hypoxia in utero or newborn life.